Loading...
Loading...
India's levothyroxine imports from BRAZIL total $3.4K across 11 shipments from 2 foreign suppliers. T&E ANALITICA - CENTRO DE PESQUISAS leads with $3.2K in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include VEEDA CLINICAL RESEARCH LIMITED. This corridor reflects India's pharmaceutical import demand for levothyroxine โ a concentrated sourcing relationship with select suppliers from BRAZIL.

T&E ANALITICA - CENTRO DE PESQUISAS is the leading Levothyroxine supplier from BRAZIL to India, with import value of $3.2K across 1 shipments. The top 5 suppliers โ T&E ANALITICA - CENTRO DE PESQUISAS, T&E ANALITICA-CENTRO CIENTIFICO โ collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) ยท Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | T&E ANALITICA - CENTRO DE PESQUISAS | $3.2K | 1 | 94.1% |
| 2 | T&E ANALITICA-CENTRO CIENTIFICO | $200 | 10 | 5.9% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | VEEDA CLINICAL RESEARCH LIMITED | $3.2K | 1 | 94.1% |
| 2 | ACME GENERICS PRIVATE LIMITED | $200 | 10 | 5.9% |
BRAZIL โ India trade corridor intelligence
As of April 2026, the Brazil to India pharmaceutical trade corridor is stable. Ports such as Jawaharlal Nehru Port Trust (JNPT), Chennai, and Mundra are operating efficiently with minimal congestion. Freight rates have remained consistent, and the exchange rate between the Indian Rupee (INR) and Brazilian Real is favorable for importers.
The Production Linked Incentive (PLI) scheme and import substitution policies are encouraging domestic manufacturing of Levothyroxine formulations. These initiatives aim to reduce import dependency and promote self-reliance in the pharmaceutical sector. While the PLI scheme may impact the volume of imports, it also presents opportunities for collaboration between Indian and Brazilian manufacturers.
India and Brazil have strengthened their trade relations through bilateral agreements, including mutual recognition of GMP standards. These agreements facilitate smoother import processes and ensure the quality of pharmaceutical products. Ongoing negotiations aim to further enhance cooperation in the pharmaceutical sector.
The landed cost for importing Levothyroxine formulations from Brazil to India includes the following components:
For a 20-foot container with a CIF value of $10,000, the total landed cost would be approximately $12,000.
CDSCO registration, import licensing, and quality testing requirements
Importing finished pharmaceutical formulations containing Levothyroxine into India requires compliance with the Central Drugs Standard Control Organization (CDSCO) regulations. The process involves obtaining an import license in Form 10 from the Directorate General of Foreign Trade (DGFT) and registering the product with CDSCO. The registration process includes submitting Form 40, a Free Sale Certificate, a Certificate of Pharmaceutical Product (COPP), and a Good Manufacturing Practice (GMP) certificate. The timeline for import drug registration can vary, but it typically takes several months to complete all necessary procedures. Specific requirements for Levothyroxine formulations under HS Code 30049099 include providing detailed product information, manufacturing details, and compliance with Indian pharmacopoeia standards.
Imported Levothyroxine formulations must undergo quality testing at CDSCO-approved laboratories. Batch-wise testing is mandatory, and a Certificate of Analysis (CoA) is required for each batch. Stability data demonstrating compliance with International Council for Harmonisation (ICH) Zone IV conditions is necessary. Products must meet the standards set by the Indian Pharmacopoeia. Upon arrival, customs drug inspectors conduct port inspections to verify compliance with these requirements.
Between 2024 and 2026, CDSCO has implemented regulatory updates affecting the import of finished pharmaceutical formulations, including Levothyroxine. The Production Linked Incentive (PLI) scheme has been introduced to encourage domestic manufacturing, potentially impacting the volume of imports. Bilateral agreements between India and Brazil have been established to facilitate pharmaceutical trade, including mutual recognition of Good Manufacturing Practices (GMP). These agreements aim to streamline the import process and ensure product quality.
Market demand, customs duty structure, and competitive landscape ยท Import duty: 17.10%
India imports finished Levothyroxine formulations to meet the demand for patented and branded products, as well as specific dosage forms not produced domestically. The domestic capacity for Levothyroxine formulations is limited, leading to a dependency on imports to fulfill market needs. The market size for Levothyroxine formulations in India is substantial, with a total export market of $77.7 million across 125 exporters to 71 countries.
The import duty structure for Levothyroxine formulations under HS Code 30049099 includes a Basic Customs Duty (BCD) of 10%, an Education Cess of 2%, a Secondary Higher Education Cess of 1%, and a Countervailing Duty (CVD) of 6%. The Social Welfare Surcharge (SWS) is 10%. The Integrated Goods and Services Tax (IGST) is 12%. There are no exemptions or preferential rates for Brazil-origin products. The total landed duty percentage is approximately 17.10%.
India sources Levothyroxine formulations from Brazil due to the availability of patented formulations and specialized dosage forms not produced domestically. Brazil's competitive advantage lies in its adherence to international quality standards and GMP compliance. Other suppliers include China, Germany, and the United States; however, Brazil's share in the Indian market is growing due to these advantages.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports Levothyroxine formulations from Brazil due to the availability of patented formulations and specialized dosage forms not produced domestically. Brazil's adherence to international quality standards and GMP compliance ensures the reliability of these products. Specific formulations, such as certain tablet strengths or combination products, are sourced from Brazil to meet the diverse needs of the Indian market.
Compared to other origins like China, the European Union, and the United States, Brazil offers competitive pricing and high-quality Levothyroxine formulations. Brazil's regulatory compliance and GMP adherence provide a level of reliability that is highly valued in the Indian market. While other suppliers may offer similar products, Brazil's unique advantage lies in its consistent product quality and favorable trade relations with India.
Potential risks for Indian importers include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should diversify their supplier base, monitor currency exchange rates, stay updated on regulatory changes, conduct regular quality audits, and maintain buffer stock to manage supply chain disruptions.
Import license checklist, document requirements, quality testing, and compliance
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Levothyroxine suppliers from BRAZIL to India include T&E ANALITICA - CENTRO DE PESQUISAS, T&E ANALITICA-CENTRO CIENTIFICO. The leading supplier is T&E ANALITICA - CENTRO DE PESQUISAS with import value of $3.2K USD across 1 shipments. India imported Levothyroxine worth $3.4K USD from BRAZIL in total across 11 shipments.
India imported Levothyroxine worth $3.4K USD from BRAZIL across 11 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Levothyroxine sourced from BRAZIL include VEEDA CLINICAL RESEARCH LIMITED, ACME GENERICS PRIVATE LIMITED. The largest buyer is VEEDA CLINICAL RESEARCH LIMITED with $3.2K in imports across 1 shipments.
The total value of Levothyroxine imports from BRAZIL to India is $3.4K USD, across 11 shipments and 2 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records โ the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
11 Verified Shipments
2 suppliers, 2 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists